WO2019184419A1 - Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée - Google Patents

Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée Download PDF

Info

Publication number
WO2019184419A1
WO2019184419A1 PCT/CN2018/118812 CN2018118812W WO2019184419A1 WO 2019184419 A1 WO2019184419 A1 WO 2019184419A1 CN 2018118812 W CN2018118812 W CN 2018118812W WO 2019184419 A1 WO2019184419 A1 WO 2019184419A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
fullerene
fatty acid
compound
acid
Prior art date
Application number
PCT/CN2018/118812
Other languages
English (en)
Chinese (zh)
Inventor
黄佳梅
黎小青
刘雅玲
朱常锋
Original Assignee
厦门福慈生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810259287.8A external-priority patent/CN108497099A/zh
Application filed by 厦门福慈生物科技有限公司 filed Critical 厦门福慈生物科技有限公司
Publication of WO2019184419A1 publication Critical patent/WO2019184419A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/02—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by the production or working-up
    • A23D7/04—Working-up

Definitions

  • the invention belongs to the field of fullerenes, and particularly relates to the use of fullerene compounds and fullerene microcapsule powders and preparation methods and applications thereof.
  • Fullerenes are the fourth crystalline form of carbon after diamond, graphite and linear carbon. Fullerenes include C 60 , C 70 and derivatives thereof. Among them, C 60 is the most representative member of the fullerene family, its molecule is aromatic, soluble in benzene is sauce red. C 60 can be obtained by a method of heating a graphite rod by electric resistance or evaporating graphite by an electric arc method. C 60 is lubricious and may become a super lubricant. The metal C 60 is superconducting and is a promising superconducting material.
  • Fullerene has a wide range of applications in daily life and social production, such as cosmetics, drug carriers, and medical diagnostics, because of its antiviral, anti-oxidant, antibacterial and other biological activities.
  • the article published by the French Fathi Moussa research team on Biomaterials published their major findings: After dispersing C 60 into olive oil and feeding the mice, it was found that C 60 has no chronic toxicity and can extend the life of mice by more than 90%.
  • degenerative diseases caused by deposition of amyloid fibrils such as Alzheimer's disease and Parkinson's syndrome, it has also been found that fullerenes can effectively prevent the formation of amyloid fibers.
  • Fullerene has poor solubility in most solvents, and usually needs to be dissolved in aromatic solvent toluene, chlorobenzene, or non-aromatic solvent carbon disulfide.
  • the poor solubility of water under normal conditions restricts its application to the body.
  • Various areas of application especially in the health industry and modern agriculture.
  • the fullerene oil solution can be made into a capsule, it is easy to carry, but it is unstable due to its instability, the oil needs to be protected from light and stored at a low temperature, and the taste is not acceptable to the public.
  • the insoluble nature of fullerenes also limits their development and application.
  • fullerene is mainly made into water-soluble derivatives such as hydrated fullerenes, fullerenes, fullerenes-vitamins C, metal fullerenes and the like.
  • water-soluble derivatives such as hydrated fullerenes, fullerenes, fullerenes-vitamins C, metal fullerenes and the like.
  • the object of the present invention is to provide a novel use of fullerene compounds and fullerene microcapsule powders and methods for their preparation and use.
  • the present invention provides the use of fullerene compounds for the preparation of fullerene microcapsule powders.
  • the fullerene microcapsule powder contains a fullerene compound, a nutritive compound oil, an edible emulsifier, and a wall material.
  • the total weight content of the fullerene compound and the nutritive compound oil is from 10% to 80% based on the total weight of the fullerene microcapsule powder and the weight of the fullerene compound
  • the content of the edible emulsifier is from 0.01% to 5%, and the weight of the wall material is from 0.01% to 80%.
  • the fullerene compound has a weight content of 1 ⁇ -5 ⁇ based on the total weight of the fullerene microcapsule powder, and the nutritional compound oil has a weight content of 50%-70%.
  • the weight content of the edible emulsifier is 4-6% by weight of the fat in the nutritional compound oil, and the weight content of the wall material is 29% to 49%.
  • the fullerene compound may be C 60 and its derivatives, C 70 and its derivatives, fullerene metal derivatives, fullerene oxygenated derivatives, organic compound modified or encapsulated rich At least one of a olefin, a modified or encapsulated fullerene derivative.
  • the oxygen atom in the fullerene oxygen-containing derivative is bonded to a carbon atom on the fullerene skeleton or to an alkylene chain.
  • the organic compound in the fullerene and fullerene derivative modified or encapsulated by the organic compound may be any of various existing organic oligomers capable of forming inclusions or complexes, for example, cyclodextrin and / or crown ether.
  • the nutritional compound oil is selected from at least one of edible oils, oil-soluble vitamins, hydrocarbons, fatty acids, higher alcohols, and esters.
  • the edible oil comprises vegetable oil and animal oil.
  • the vegetable oil is preferably selected from the group consisting of soybean oil, rapeseed oil, palm oil, olive oil, sunflower oil, safflower oil, sea buckthorn seed oil, corn oil, safflower oil, perilla seed oil, tea seed oil, and camellia seed.
  • the animal oil is preferably selected from at least one of lard, tallow, sheep oil, fish oil, horse oil and sea turtle oil.
  • the hydrocarbons are preferably squalane and/or squalene.
  • the fatty acid is preferably selected from at least one of oleic acid, linoleic acid, linolenic acid, conjugated linoleic acid, DHA, stearic acid, lauric acid, arachidonic acid, and EPA.
  • the higher alcohol is preferably at least one selected from the group consisting of octyldodecanol, lauryl alcohol, phytosterol, cholesterol, and stearyl alcohol.
  • the esters are preferably conjugated linoleic acid triglycerides and/or linoleic acid glycerides.
  • the nutritional compound oil is linseed oil, safflower seed oil, perilla seed oil, camellia seed oil, sunflower oil, soybean oil, olive oil, pumpkin seed oil, evening primrose oil, borage Oil, sea buckthorn fruit oil, sea buckthorn seed oil, peony seed oil, walnut oil, celery oil, sea buckthorn oil, sesame oil, linoleic acid, linolenic acid, linoleic acid triglyceride, conjugated linoleic acid, conjugate A combination of two or more of linoleic acid triglycerides.
  • the edible emulsifier may be one which has hydrophilicity and lipophilicity in various molecular structures and has surface activity due to amphiphilicity, and may be an anionic surfactant, a cationic surfactant, or a non- An ionic surfactant or an amphoteric surfactant.
  • the edible emulsifier include, but are not limited to, sucrose fatty acid esters, polyglycerin fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, sodium caseinate, lecithin, stearin Sodium, monoglyceride organic acid fatty acid ester, betaine, amino acid salt, glyceryl succinate fatty acid ester, sodium stearoyl lactylate, Tween-80, Span-80, polyglycerol ester, propylene glycol fatty acid ester and polysorbate At least one of fatty acid esters; or, the edible emulsifier is A, or a mixture of A and B, and A is one or both of oligofructose, resistant dextrin, skimmed milk powder, and B is cheese One of sodium acidate, mono-, diglycerin fatty acid ester, sodium starch octenyl succinate, ascorbic acid, sodium ascorbic
  • the wall material functions to form a film having a certain strength and to improve the microencapsulation efficiency.
  • the wall material is preferably a water-soluble polymer material, and may be specifically selected from the group consisting of maltodextrin (DE18 or DE20), soy protein isolate (SPI), gum arabic (GA), ⁇ -cyclodextrin, starch (corn starch, modified).
  • the wall material is a mixture of two or more of soy protein isolate, xanthan gum, modified starch, gelatin, carboxymethyl cellulose, and maltodextrin.
  • the nutritional fatty acid ratio of the nutritional compound oil is saturated fatty acid: monounsaturated fatty acid: polyunsaturated fatty acid weight ratio is 1: (0.5-2): (0.5-2), in the polyunsaturated fatty acid Linoleic acid: linolenic acid weight ratio is 1: (0.5-2).
  • the nutritional fatty acid ratio of the nutritional compound oil is saturated fatty acid: monounsaturated fatty acid: polyunsaturated fatty acid weight ratio is 1: (0.5-1.5): (0.5-1.5), in the polyunsaturated fatty acid Linoleic acid: linolenic acid weight ratio is 1: (0.5-1.5).
  • the nutritional fatty acid ratio of the nutritional compound oil is saturated fatty acid: monounsaturated fatty acid: polyunsaturated fatty acid weight ratio is 1:1:1, linoleic acid: linolenic acid weight in the polyunsaturated fatty acid The ratio is 1:1.
  • the fullerene microcapsule powder further contains a stabilizer and/or a glidant.
  • the stabilizer is present in an amount of from 0.01% to 20% by weight based on the total weight of the fullerene microcapsule powder, and the glidant is present in an amount of from 0.01% to 2% by weight.
  • the stabilizer may be any one of various substances capable of stabilizing the performance of the fullerene capsule, and may be an organic acid having a chelate or a salt thereof, and specific examples thereof include, but are not limited to, erythorbic acid and a salt thereof, gallic acid. And a derivative thereof, at least one of gluconic acid, sodium tripolyphosphate, complex phosphate, dipotassium hydrogen phosphate, sodium polyphosphate, sodium metaphosphate, sodium carboxymethylcellulose, and agar.
  • the glidant is capable of imparting better fluidity to the components forming the fullerene capsule for ease of molding.
  • Specific examples of the glidant include, but are not limited to, at least one of a silicate, a stearate, an iron salt, a phosphate, a polysaccharide, a talc, calcium carbonate, and zinc dioxide.
  • the silicate may be at least one selected from the group consisting of silica, calcium silicate, sodium aluminum silicate, magnesium silicate, and sodium aluminosilicate.
  • the stearate may be selected from at least one of sodium stearate, calcium stearate, aluminum stearate, and zinc stearate.
  • the iron salt may be ammonium ammonium citrate and/or sodium ferric hydride.
  • the phosphate may be calcium phosphate and/or magnesium phosphate.
  • the polysaccharide may be a depolymerized starch and/or a microcrystalline depolymerized cellulose.
  • the fullerene microcapsule powder is prepared in the following manner (1) or mode (2):
  • Oil phase preparation the nutrient compound oil is formulated according to a ratio of fatty acids, and then the fullerene compound is sterilized and dissolved in a nutrient compound oil to form a compound oil compound, and then the edible emulsifier is dissolved.
  • an oil phase is obtained;
  • Aqueous phase preparation dissolving the wall material in hot water to obtain an aqueous phase; preferably, the temperature of the hot water is 60-80 ° C;
  • the mixing is performed under shearing conditions, and the mixing conditions include a temperature of 50-80 ° C, a shear rate of 10000-15000 rpm, and a time of 2 10min.
  • the homogenous pressure is 30-35 MPa, and the number of times is 2-5 times.
  • the conditions of the spray drying include an inlet air temperature of 180-240 ° C and an outlet air temperature of 75-85 ° C.
  • the present invention also provides a fullerene microcapsule powder, wherein the fullerene microcapsule powder contains a fullerene compound, a nutrient compound oil, an edible emulsifier, and a wall material.
  • the total weight content of the fullerene compound and the nutritive compound oil is from 10% to 80% based on the total weight of the fullerene microcapsule powder and the weight of the fullerene compound
  • the content of the edible emulsifier is from 0.01% to 5%, and the weight of the wall material is from 0.01% to 80%.
  • the fullerene compound has a weight content of 1 ⁇ -5 ⁇ based on the total weight of the fullerene microcapsule powder, and the nutritional compound oil has a weight content of 50%-70%.
  • the weight content of the edible emulsifier is 4-6% by weight of the fat in the nutritional compound oil, and the weight content of the wall material is 29% to 49%.
  • the fullerene microcapsule powder further contains a stabilizer and/or a glidant.
  • the stabilizer is present in an amount of from 0.01% to 20% by weight based on the total weight of the fullerene microcapsule powder, and the glidant is present in an amount of from 0.01% to 2% by weight.
  • the fullerene microcapsule powder has a particle diameter of from 5 to 500 ⁇ m.
  • the preparation method of the fullerene microcapsule powder provided by the invention comprises:
  • Oil phase preparation the nutrient compound oil is formulated according to a ratio of fatty acids, and then the fullerene compound is sterilized and dissolved in a nutrient compound oil to form a compound oil compound, and then the edible emulsifier is dissolved.
  • an oil phase is obtained;
  • Aqueous phase preparation dissolving the wall material in hot water to obtain an aqueous phase; preferably, the temperature of the hot water is 60-80 ° C;
  • the present invention also provides the fullerene microcapsule powder for use in the preparation of beverages, foods, beauty products, hangover products, and for preventing and/or treating liver cancer, neurodegenerative diseases (such as Parkinson's disease, senile dementia). And the application of drugs in tumors.
  • neurodegenerative diseases such as Parkinson's disease, senile dementia
  • the fullerene compound cannot be completely dissolved in the fat or oil, and the amount of addition is not proportional to the solubility. If the dissolution is particularly small, the process is simple and the cost is low, but the amount of microcapsule powder ingested will increase accordingly, and accordingly, the amount of oil to be ingested will also increase, which does not meet the requirements of human nutrition; High, complex, technically difficult, and the cost of fullerenes will increase a lot.
  • the fullerene When the fullerene is added in an amount of 0.1 ⁇ to 5 Torr, it can be dissolved by a simple stirring method, but at this time, since the amount of fullerene added is too low, the oxidation resistance is not ideal; when the amount is more than 5 ⁇ The stirring cannot be completely dissolved, the undissolved fullerene is treated by centrifugation, and the residual fullerene is not cleaned.
  • the Applicant's inventors have discovered through hard work that when a fullerene compound is formulated with a nutrient compound oil, a wall material, an edible emulsifier, and optionally a stabilizer and a glidant, the microcapsule powder can be A good antioxidant effect is achieved at a lower amount of fullerene (0.1 ⁇ -5 Torr).
  • fullerene intake of 8mg / day / person can show significant antioxidant effect, which is equivalent to the intake of fullerene microcapsule powder amount of 20g / day / people.
  • the weight content of the nutritional compound oil in the fullerene microcapsule powder provided by the present invention is particularly preferably from 50% to 70%.
  • the fullerene is made into a microcapsule powder and can be ingested as a food, and is more flexible in terms of taste and intake.
  • the use of fullerenes as microcapsules greatly enhances their field of application.
  • the fullerene microcapsule powder of the invention adopts a food material as a wrapping material, and transforms it into a nutritious drink with convenient consumption and various flavors, and can be taken in a short-term or long-term manner, and has anti-aging and anti-cancer health effects, and has a high Promotion value.
  • the invention can effectively overcome the fact that the fullerene compound and the fullerene oil solution are difficult to preserve by using a fullerene compound, a nutrient compound oil, a wall material, an edible emulsifier, and an optional stabilizer and a glidant. It is easy to oxidize, accelerates discoloration or fading of pigments, easily hardens proteins, reduces digestibility, destroys vitamins, easily causes decomposition of nutrients, and produces toxic substances, which can significantly increase fullerene compounds.
  • the stability is such that the fullerene compound can fully exert its activity.
  • the fullerene microcapsule powder provided by the invention has the advantages of being soluble in water, high stability, convenient transportation, easy storage, and more flexible and diversified in taste and ingestion manner as a raw material of food or medicine.
  • the fullerene microcapsule powder provided by the invention overcomes the limitations of the prior art, and enables fullerenes and their derivatives to be applied in the field of body adaptability, and provides a new loading mode--microencapsulation.
  • the fullerene microcapsule powder provided by the invention can greatly broaden the application of fullerene compounds in various fields, for example, in the health industry, the fullerene microcapsule powder can be formulated into fullerene-containing micro-capsules.
  • the medical application can be used for the preparation of a medicament for preventing and/or treating diseases such as liver cancer, neurodegenerative diseases (such as Parkinson's disease, senile dementia), and tumors.
  • FIG. 1 is a schematic view showing the microstructure of a fullerene microcapsule powder provided by the present invention
  • FIG. 2 is a graph showing POV values of fullerene microcapsule powder and fullerene oil solution as a function of storage time
  • Figure 3 is a graph showing the fullerene content in fullerene microcapsule powder and fullerene oil solution as a function of storage time.
  • Example 1 Project Fullerene oil solution Wall material Edible emulsifier stabilizer Glidant Example 1 50 46 2 1 1 Example 2 33.3 62.7 2 1 1 Example 3 25 71 2 1 1 Example 4 50 47 1 0.5 1.5
  • Preparation method 60% by weight of maltodextrin (wall material), 2% by weight of sodium caseinate (edible emulsifier), 1% by weight of dipotassium hydrogen phosphate (stabilizer) and 1% by weight of dioxide Silicon (glidant) and distilled water were mixed and dissolved, and a 50 wt% fullerene nutrient compound oil solution (obtained in Preparation Example 1) was added to prepare an emulsion. The emulsification was sheared at 11200 rpm for 5 min at 60 °C.
  • the sheared emulsion was immediately homogenized three times by high pressure homogenizer, the homogenization pressure was 30-35 MPa, and the homogenized emulsion was spray-dried, the inlet air temperature was 200 ° C, and the outlet air temperature was 82 ° C.
  • the fullerene microcapsule powder is obtained, and its microscopic morphology is shown in FIG. It can be seen from the results of Fig. 1 that the fullerene microcapsule powder has a particle diameter of 5-20 ⁇ m and a hollow spherical or elliptical shape inside, which is due to the occurrence of bubbles inside the particle when the outer shell of the product is rapidly formed.
  • the fullerene microcapsule powder has a spherical or elliptical shape, and the surface is smooth, dense, and free of cracks, and some of the particles have a slight depression and shrinkage, which is unique to the spray drying process.
  • Preparation method 60 ° C, 62.7 wt% maltodextrin (wall material), 2 wt% sodium caseinate (edible emulsifier), 1 wt% dipotassium hydrogen phosphate (stabilizer) and 1 wt% of two Silica (glidant) and distilled water were mixed and dissolved, and a 33.3 wt% fullerene olive oil solution (obtained in Preparation Example 2) was added to prepare an emulsion. The emulsification was sheared at 11200 rpm for 5 min at 60 °C.
  • the sheared emulsion was immediately homogenized three times by high pressure homogenizer, the homogenization pressure was 30-35 MPa, and the homogenized emulsion was spray-dried, the inlet air temperature was 200 ° C, and the outlet air temperature was 82 ° C.
  • a fullerene microcapsule powder having a particle diameter of 100 to 200 ⁇ m is obtained.
  • Preparation method at 60 ° C, 71 wt% of maltodextrin (wall material), 2 wt% of sodium caseinate (edible emulsifier), 1 wt% of dipotassium hydrogen phosphate (stabilizer) and 1 wt% of dioxide Silicon (glidant) and distilled water were mixed and dissolved, and a 25 wt% fullerene sea buckthorn seed oil solution (obtained in Preparation Example 3) was added to prepare an emulsion. The emulsification was sheared at 11200 rpm for 5 min at 60 °C.
  • the sheared emulsion was immediately homogenized three times by high pressure homogenizer, the homogenization pressure was 30-35 MPa, and the homogenized emulsion was spray-dried, the inlet air temperature was 200 ° C, and the outlet air temperature was 82 ° C.
  • a fullerene microcapsule powder having a particle diameter of 225 to 305 ⁇ m is obtained.
  • Preparation method 9.4 wt% soy protein isolate (wall material) was dissolved in distilled water, temperature-controlled magnetic stirrer treatment at 80 ° C for 30 min, cooling; 0.5 wt% sodium carboxymethyl cellulose (stabilizer) and 1.5 wt% Silica (glidant) is dissolved in distilled water, and then 37.6% of maltodextrin (wall material) is mixed with the above-mentioned soy protein isolate solution, sodium carboxymethylcellulose and silica, and mixed to 50% by weight.
  • Example 5 Sterile fullerene Edible emulsifier Nutritional compound oil Wall material
  • Example 6 1 ⁇ 3.0% 50% 46.90%
  • Example 6 5 ⁇ 3.5% 70% 26.00%
  • Example 7 2.5 ⁇ 2.5% 50% 47.25%
  • Example 8 3 ⁇ 3.0% 60% 36.70%
  • the weight ratio of saturated fatty acid, monounsaturated fatty acid to polyunsaturated fatty acid is 1:1:1
  • the weight ratio of linoleic acid to linolenic acid in polyunsaturated fatty acid It is 1:1.
  • the prepared fullerene microcapsule powder has an antioxidant capacity of 125 times that of vitamin C as determined by an in vitro ⁇ -carotene oxidation method.
  • the production process is the same as in the fifth embodiment.
  • the prepared fullerene microcapsule powder has an antioxidant capacity of 125 times that of vitamin C as determined by an in vitro ⁇ -carotene oxidation method.
  • the production process is the same as in the fifth embodiment.
  • the prepared fullerene microcapsule powder has an antioxidant capacity of 125 times that of vitamin C as determined by an in vitro ⁇ -carotene oxidation method.
  • the production process is the same as in the fifth embodiment.
  • the prepared fullerene microcapsule powder has an antioxidant capacity of 125 times that of vitamin C as determined by an in vitro ⁇ -carotene oxidation method.
  • the Schaler oven method was used to test the oxidative stability of fullerene microcapsule powder and the fullerene content in fullerene microcapsule powder. Specifically, 12 dry and clean 50 mL screw bottles were added to each group, and 1 was added. The /2-volume fullerene microcapsule powder was stored in an oven at 60 ⁇ 2°C and 60% humidity for accelerated storage. A test bottle was taken every 5 days, and the POV value and fullerene content of the sample were measured. After 60 days, End the test.
  • Sample pretreatment using toluene as solvent, using ultrasonic vibration to break the wall and extract the oil, weigh 5g sample in 50mL colorimetric tube, add 25mL toluene, put it in the ultrasonic cleaner water tank, ultrasonically shake for 30 minutes, take out, filter, and use The toluene was sufficiently washed, the filtrate was combined (the above operation was repeated twice), toluene was recovered by a rotary evaporator, heated in a water bath, toluene was fully exerted, and it was placed in a vacuum drying oven, and toluene was further removed at 50 ° C for use.
  • the POV value was determined according to the method specified in GB/T5538-2005 Determination of peroxide value of animal and vegetable oils.
  • FIG. 2 is a graph showing the POV value of the fullerene microcapsule powder obtained in Example 1 and the corresponding fullerene oil solution as a function of storage time during high temperature storage.
  • the fullerene microcapsule powder is kept at an acceptable temperature within 60 °C. The time is 35d, while the fullerene oil solution under the same conditions can only be stored for 20d.
  • Sample pretreatment using toluene as solvent, using ultrasonic vibration to break the wall and extract the oil, weigh 5g sample in 50mL colorimetric tube, add 25mL toluene, put it in the ultrasonic cleaner water tank, ultrasonically shake for 30 minutes, take out, filter, and use The toluene was thoroughly washed, the filtrate was combined (the above operation was repeated twice), toluene was recovered by a rotary evaporator, heated in a water bath, and the mixture was placed in toluene, placed in a vacuum drying oven, and toluene was further removed at 50 ° C for use.
  • the fullerene microcapsule powder sample was pretreated and the fullerene oil solution and the control fullerene oil solution were filtered, and 1 mL was added to 3 mL of a toluene solution to dilute and dissolve.
  • the column was analyzed by high performance liquid chromatography with a standard solution concentration of 0.3 mg/mL. Control peak area: 21296401 mAU*min.
  • Figure 3 is a graph showing the fullerene content of the fullerene microcapsule powder obtained in Example 1 and the corresponding fullerene oil solution as a function of storage time during high temperature storage.
  • the results in Figure 3 show that the content of fullerenes in the experimental group and the control group remained unchanged over time.
  • the fullerene content in the fullerene oil solution began to decrease.
  • the fullerene content in the fullerene microcapsules began to decrease on the 15th day. This indicates that the fullerene microcapsule powder can protect the fullerene and is not easily oxidized.
  • Test animals and test group 40 healthy pigs with uniform body weight, uniform male-female ratio and similar age were randomly divided into 4 groups, 10 in each group, one experimental group, one control group, and one repeat group. , carry out feeding experiments.
  • test diet was divided into two groups, the control group and the experimental group, the control group added the basic diet, and the experimental group added 1wt% fullerene microcapsule powder on the basis of the control group.
  • the test period is from March 30, 2018 to May 30, for a total of 60 days.
  • Feeding management 60 days in the whole experiment, 40 pigs were kept in the same pig house, and each group was kept in 10 pigs per lap. It was well ventilated and the temperature was suitable. It was regularly disinfected according to the pig quarantine program, and nipple water was used. The device provides sufficient clean drinking water, and the test pigs are fed 3 times a day, free to eat and drink. Observe the pig's intake, drinking water, stool color and morbidity, and make daily records. Other management is carried out according to the normal management of the farm.
  • each pig with a weight close to the average weight of the treatment was selected, and the anterior vena cava was collected.
  • the blood was quickly taken out and poured into an anticoagulant blood vessel with anticoagulant.
  • the automatic animal blood cell analyzer measures the total number of red blood cells, total white blood cells, lymphocytes, intermediate cells and granulocytes in whole blood.
  • Test results The effect of the fullerene microcapsule powder obtained in Example 1 on serum physiological indexes in pigs is shown in Table 3. The results showed that compared with the control group, the experimental group significantly increased (P ⁇ 0.05) the number of blood lymphocytes, and significantly increased (P ⁇ 0.01) the number of granulocytes, but the total number of white blood cells, the number of intermediate cells, the total number of red blood cells and Hemoglobin had no significant effect (P>0.05).
  • Example 4 The effect of the fullerene microcapsule powder obtained in Example 1 on immunoglobulin in pig serum is shown in Table 4. The results showed that the experimental group could significantly increase the serum IgM content (P ⁇ 0.05), but had no significant effect on IgA and IgG (P>0.05).
  • fullerene microcapsule powder significantly increased the number of lymphocytes and granulocytes in pig blood compared with no addition, but had no significant effect on other blood physiological indicators and immunoglobulin.
  • fullerene microcapsule powder can promote the development of immune organs in pigs and promote the formation of lymphocytes and granulocytes, thereby improving immunity.
  • Group Control group test group White blood cell count, ⁇ 10 9 /L 18.10 ⁇ 0.69 20.16 ⁇ 1.20 Number of lymphocytes, ⁇ 10 9 /L 7.50 a ⁇ 1.35 8.65 ab ⁇ 1.24 Intermediate cell, ⁇ 10 9 /L 2.57 ⁇ 0.87 3.26 ⁇ 0.62 Granulocytes, ⁇ 10 9 /L 7.28 b ⁇ 1.03 11.16 a ⁇ 0.98 Red blood cells, ⁇ 10 9 /L 5.45 ⁇ 0.21 5.69 ⁇ 0.65 Hemoglobin, g/L 92.1 ⁇ 3.10 96.33 ⁇ 4.02
  • Test Example 2 Experiment of improving immunity by fullerene microcapsule powder
  • Test Example 3 Effect experiment of fullerene microcapsule powder for health care
  • Test Example 4 Detoxification product containing fullerene microcapsule powder and effect verification experiment
  • mice were respectively treated with 0.26ml/20g, 0.28ml/20g, 0.30ml/20g, 0.32ml/20g, 0.34ml/20g, 0.36ml/20g wine solution (56 degree red star Erguotou).
  • Stomach 6 in each group.
  • the amount of alcohol required to cause the disappearance of righting reflex in the mice without death of the mice was observed.
  • the experimental results are shown in Table 5: The 0.30 ml/20 g wine solution was selected for subsequent experiments.
  • mice were randomly divided into 4 groups: model group (administered volumetric saline), low-dose group (administered 0.1ml/20g), medium-dose group (administered 0.2ml/20g), high dose (administered 0.3ml) /20g), 10 per group.
  • model group administered volumetric saline
  • low-dose group administered 0.1ml/20g
  • medium-dose group administered 0.2ml/20g
  • high dose administered 0.3ml
  • 10 per group 10 per group.
  • Each group of mice was fasted for 12 h and administered once. After 30 minutes, each group was given 15 ml/kg (based on pre-experiment data) and the weight of 56 °C Beijing Erguotou wine was intragastrically administered.
  • the drunkenness time of the mice was observed and the drunk rate within 24 hours was calculated.
  • mice are drunk or not, whether the righting reflex disappears as the standard: after the mice are drunk, put them back down and gently put them into the squirrel cage. If the mouse is kept in a downward posture for more than 30 s, it is considered that the righting reflex Disappeared, that is drunk. Observe the time of waking up the mice (from the time of righting reflex to awake) and calculate the mortality within 24 hours. The results are shown in Tables 6-7. It can be seen that the fullerene microcapsule powder provided by the present invention has a good hangover effect.
  • control group was administered dH 2 O.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de fullerène, une poudre de microcapsule de fullerène, un procédé de préparation et une application associée. La poudre de microcapsule de fullerène contient un fullerène, des huiles nutritionnelles composées, un émulsifiant comestible et un matériau de paroi. La poudre de microcapsule de fullerène peut être utilisée dans la préparation d'une boisson, d'un aliment, d'un produit de beauté, d'un produit pour traiter la xylostomiase, ou d'un médicament pour la prévention et le traitement du cancer du foie, d'une maladie neurodégénérative ou de tumeurs.
PCT/CN2018/118812 2018-03-27 2018-12-03 Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée WO2019184419A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810259287.8 2018-03-27
CN201810259287.8A CN108497099A (zh) 2018-03-27 2018-03-27 富勒烯被用于制备成富勒烯微囊粉的用途
CN201811123023.6 2018-09-26
CN201811123023.6A CN110301483A (zh) 2018-03-27 2018-09-26 富勒烯类化合物的用途以及富勒烯微囊粉及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2019184419A1 true WO2019184419A1 (fr) 2019-10-03

Family

ID=68060863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/118812 WO2019184419A1 (fr) 2018-03-27 2018-12-03 Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée

Country Status (1)

Country Link
WO (1) WO2019184419A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020068817A1 (fr) * 2018-09-24 2020-04-02 The Cleveland Clinic Foundation Fullerènes pour le traitement de maladies et d'états
CN111150087A (zh) * 2019-12-31 2020-05-15 西昌市正中食品有限公司 一种包埋壁材以及微胶囊苦荞提取物、制备工艺
CN113057182A (zh) * 2021-03-18 2021-07-02 广西壮族自治区林业科学研究院 一种利用植物精油制备脂质体微胶囊长效驱蚊膏的方法
WO2021175240A1 (fr) * 2020-03-06 2021-09-10 厦门福纳新材料科技有限公司 Application de fullerène et d'un dérivé associé lors de la régulation de la flore intestinale
CN114762659A (zh) * 2021-01-11 2022-07-19 北京福纳康生物技术有限公司 环糊精包合富勒烯及其制备方法和应用
WO2022197376A1 (fr) * 2021-03-15 2022-09-22 Sinapu Llc Poly di-galloyles de phosphonate de fullerène et procédés
CN115317402A (zh) * 2022-07-05 2022-11-11 北京福纳康生物技术有限公司 一种水溶性富勒烯壳多糖复合物及其制备方法和应用
CN116555328A (zh) * 2023-05-12 2023-08-08 东北林业大学 文冠果XsMYB113-1基因在植物遗传转化体系建立中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102987382A (zh) * 2012-08-08 2013-03-27 辽宁省大连海洋渔业集团公司 磷虾油微囊粉及其制备方法
CN103705388A (zh) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
CN103826472A (zh) * 2011-06-30 2014-05-28 法特希·穆萨 富勒烯及其保持哺乳动物身体健康和延长哺乳动物预期寿命的用途
CN107753513A (zh) * 2016-08-15 2018-03-06 北京福纳康生物技术有限公司 富勒烯在制备药物中的用途以及保护肝脏的药物
CN108497099A (zh) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 富勒烯被用于制备成富勒烯微囊粉的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103826472A (zh) * 2011-06-30 2014-05-28 法特希·穆萨 富勒烯及其保持哺乳动物身体健康和延长哺乳动物预期寿命的用途
CN102987382A (zh) * 2012-08-08 2013-03-27 辽宁省大连海洋渔业集团公司 磷虾油微囊粉及其制备方法
CN103705388A (zh) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
CN107753513A (zh) * 2016-08-15 2018-03-06 北京福纳康生物技术有限公司 富勒烯在制备药物中的用途以及保护肝脏的药物
CN108497099A (zh) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 富勒烯被用于制备成富勒烯微囊粉的用途

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020068817A1 (fr) * 2018-09-24 2020-04-02 The Cleveland Clinic Foundation Fullerènes pour le traitement de maladies et d'états
CN111150087A (zh) * 2019-12-31 2020-05-15 西昌市正中食品有限公司 一种包埋壁材以及微胶囊苦荞提取物、制备工艺
CN111150087B (zh) * 2019-12-31 2022-03-18 西昌市正中食品有限公司 一种含苦荞提取物的微胶囊、及其制备工艺
WO2021175240A1 (fr) * 2020-03-06 2021-09-10 厦门福纳新材料科技有限公司 Application de fullerène et d'un dérivé associé lors de la régulation de la flore intestinale
CN114762659A (zh) * 2021-01-11 2022-07-19 北京福纳康生物技术有限公司 环糊精包合富勒烯及其制备方法和应用
WO2022197376A1 (fr) * 2021-03-15 2022-09-22 Sinapu Llc Poly di-galloyles de phosphonate de fullerène et procédés
CN113057182A (zh) * 2021-03-18 2021-07-02 广西壮族自治区林业科学研究院 一种利用植物精油制备脂质体微胶囊长效驱蚊膏的方法
CN113057182B (zh) * 2021-03-18 2022-01-28 广西壮族自治区林业科学研究院 一种利用植物精油制备脂质体微胶囊长效驱蚊膏的方法
CN115317402A (zh) * 2022-07-05 2022-11-11 北京福纳康生物技术有限公司 一种水溶性富勒烯壳多糖复合物及其制备方法和应用
CN116555328A (zh) * 2023-05-12 2023-08-08 东北林业大学 文冠果XsMYB113-1基因在植物遗传转化体系建立中的应用

Similar Documents

Publication Publication Date Title
WO2019184419A1 (fr) Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée
CN110301483A (zh) 富勒烯类化合物的用途以及富勒烯微囊粉及其制备方法和应用
AU2020373489B2 (en) Microcapsule, preparation method and application thereof
Ye et al. Microencapsulation of active ingredients in functional foods: From research stage to commercial food products
CN102036661B (zh) 维生素衍生物及其用途
JP6491102B2 (ja) プロバイオティクス、架橋性試薬、変性タンパク質、ポリオール可塑剤及びトレハロースを含む微小粒子
Jampilek et al. Potential of nanonutraceuticals in increasing immunity
US10898442B2 (en) Microencapsulates containing stabilised lipid, and methods for the production thereof
JP5490795B2 (ja) 栄養補給組成物のための改善された乳化系
CN107669657B (zh) 一种含较多双键脂溶性营养素高稳定性微胶囊的制备方法
Du et al. Omega‐3 polyunsaturated fatty acid encapsulation system: Physical and oxidative stability, and medical applications
CN107319525A (zh) 一种减肥减脂专用型临床营养配方及其制备方法
JP7458788B2 (ja) カプセル化された栄養及び医薬組成物
CN102131407A (zh) 含有非极性化合物的组合物
CN106578092A (zh) 一种儿童奶粉及其制作方法
CN104758315A (zh) 一种利用玉米醇溶蛋白包裹鱼油的方法
CN107441217B (zh) 一种富含α-亚麻酸的口服乳剂及其制备方法
CN107660620A (zh) 一种羊基油脂微胶囊粉末及其制备方法
TW201236578A (en) Nutritional products comprising beta-hydroxy-beta-methylbutyrate
Homroy et al. Role of encapsulation on the bioavailability of omega‐3 fatty acids
JP2019135217A (ja) 粉状組成物、粉状組成物の製造方法、ドライアイ改善剤、肌質改善剤、飲食物、化粧品、及びペットフード
Gao et al. Advances in encapsulation systems of Antarctic krill oil: From extraction to encapsulation, and future direction
CN101912388B (zh) 逆向蒸发-高压微射流制备中链脂肪酸-维生素c脂质体
Jiang et al. Impact of wall materials and DHA sources on the release, digestion and absorption of DHA microcapsules: Advancements, challenges and future directions
JP2011240221A (ja) 脂溶性機能性化合物エマルション及びその製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18912161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18912161

Country of ref document: EP

Kind code of ref document: A1